Intradigm Corp., a drug development company focused on RNA interference (RNAi) therapeutics, has raised $16 million in Series A recap funding co-led by Alta Partners and Frazier Healthcare Ventures. Other backers include MediBic Alliance/Daiichi and Genentech, while return backers include Emerging Technology Partners and Novartis Ventures. The company first raised VC funding in 1999, and is moving its headquarters from
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: subscriptions@peimedia.com.